Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Neurobiology of Disease

• Publication date

  1999-12-01

• Fields of study

  Biology, Medicine, Psychology

• Identifiers
  DOI 10.1006/NBDI.1999.0259PMID 10600402
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rat DARPP-32: Cloning, sequencing, and characterization of the cDNA

  2008cited by this paper
• Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment.

  1999cited by this paper
• Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.

  1998cited by this paper
• L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA

  1998cited by this paper
• Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease.

  1998cited by this paper
• D1-Receptor-related priming is attenuated by antisense-meditated 'knockdown' of fosB expression.

  1998cited by this paper
• A Complex Program of Striatal Gene Expression Induced by Dopaminergic Stimulation

  1998cited by this paper
• Cocaine and the AP‐1 Transcription Factor Complex

  1998cited by this paper
• A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease

  1997cited by this paper
• Chronic Fos-Related Antigens: Stable Variants of ΔFosB Induced in Brain by Chronic Treatments

  1997cited by this paper
• Drug-Induced Movement Disorders

  1997cited by this paper
• Alterations in opioid receptor binding in Parkinson's disease patients with levodopa‐induced dyskinesias

  1997cited by this paper
• Spatiotemporal dynamics of CREB phosphorylation: transient versus sustained phosphorylation in the developing striatum.

  1996cited by this paper
• Expression of FosB during mouse development: normal development of FosB knockout mice.

  1996cited by this paper
• A defect in nurturing in mice lacking the immediate early gene fosB.

  1996cited by this paper
• Opioid analgesics and antagonists

  1996cited by this paper
• Chronic Alterations in Dopaminergic Neurotransmission Produce a Persistent Elevation of ΔFosB‐like Protein(s) in both the Rodent and Primate Striatum

  1996cited by this paper
• The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.

  1996cited by this paper
• Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum.

  1995cited by this paper
• Oral stereotypy induced by amphetamine microinjection into striatum: an anatomical mapping study.

  1994cited by this paper
• Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments.

  1994cited by this paper
• Induction of the rat prodynorphin gene through Gs-coupled receptors may involve phosphorylation-dependent derepression and activation

  1994cited by this paper
• Ventrolateral striatal dopamine depletions impair feeding and food handling in rats.

  1993cited by this paper
• Molecular pathways of pain: Fos/Jun-mediated activation of a noncanonical AP-1 site in the prodynorphin gene.

  1991cited by this paper
• Both products of the fosB gene, FosB and its short form, FosB/SF, are transcriptional activators in fibroblasts.

  1991cited by this paper
• Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue.

  1991cited by this paper
• A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells.

  1991cited by this paper
• Levodopa‐induced dyskinesia

  1990cited by this paper
• Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1989cited by this paper
• Pathogenesis of dyskinesias in parkinson's disease

  1989cited by this paper
• The functional anatomy of basal ganglia disorders.

  1989cited by this paper
• Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.

  1989cited by this paper
• Cloning and expression of a rat D2 dopamine receptor cDNA

  1988cited by this paper
• Motor functions of the striatum in the rat: critical role of the lateral region in tongue and forelimb reaching.

  1988cited by this paper
• Glutamic acid decarboxylase cDNA: nucleotide sequence encoding an enzymatically active fusion protein

  1987cited by this paper
• Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease.

  1986cited by this paper
• Goodman and Gilman's the Pharmacological Basis of Therapeutics

  1986cited by this paper
• Sequence and expression of the rat prodynorphin gene.

  1985cited by this paper
• Molecular cloning and sequence determination of rat preproenkephalin cDNA: sensitive probe for studying transcriptional changes in rat tissues.

  1984cited by this paper
• Effect of naloxone on the "on-off' syndrome in patients receiving long-term levodopa therapy.

  1982cited by this paper
• Experimental Design: Procedures for the Behavioral Sciences

  1969cited by this paper
• Multivariate procedures for the behavioral sciences

  1965cited by this paper
• Estimation of nuclear population from microtome sections

  1946cited by this paper

• Long-term continuous theta burst stimulation ameliorates L-DOPA-induced dyskinesia in Parkinsonian rats through modulation of the cerebello-thalamo-striatal circuit.

  2026cites this paper
• The Role of ΔFosB in the Pathogenesis of Levodopa-Induced Dyskinesia: Mechanisms and Therapeutic Strategies

  2025cites this paper
• Serotonin-dopamine interactions in psychostimulant-induced gene regulation: SSRI antidepressants potentiate gene regulation by methylphenidate (Ritalin) in the striatum and enhance behavioral profile indicative of addiction liability in rodents.

  2025cites this paper
• Persistent COX-2 upregulation in L-DOPA-induced dyskinesia is unaffected by inhibition with celecoxib.

  2025cites this paper
• Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.

  2025cites this paper
• Rewarding properties of L-Dopa in experimental parkinsonism are mediated by sensitized dopamine D1 receptors in the dorsal striatum

  2024cites this paper
• Transcranial Magnetic Stimulation Attenuates Dyskinesias and FosB and c-Fos Expression in a Parkinson’s Disease Model

  2024cites this paper
• AMPK-mediated autophagy pathway activation promotes ΔFosB degradation to improve levodopa-induced dyskinesia.

  2024cites this paper
• Behavioral analysis of motor and non-motor impairment in rodent models of Parkinson's disease

  2024cites this paper
• 5-HT4R agonism reduces L-DOPA-induced dyskinesia via striatopallidal neurons in unilaterally 6-OHDA lesioned mice.

  2024cites this paper
• Activation of mGlu2/3 receptors in the striatum alleviates L-DOPA-induced dyskinesia and inhibits abnormal postsynaptic molecular expression.

  2023cites this paper
• Chronic H3R activation reduces L-Dopa-induced dyskinesia, normalizes cortical GABA and glutamate levels, and increases striatal dopamine D1R mRNA expression in 6-hydroxydopamine-lesioned male rats

  2023cites this paper
• Prenatal Exposition to Haloperidol: A Preclinical Narrative Review.

  2023cites this paper
• Modulation by Estradiol of L-Dopa-Induced Dyskinesia in a Rat Model of Post-Menopausal Hemiparkinsonism

  2022cites this paper
• Phosphodiesterase 10A Inhibition Modulates the Corticostriatal Activity and L-DOPA-Induced Dyskinesia

  2022cites this paper
• Cerebellar stimulation prevents Levodopa-induced dyskinesia in mice and normalizes activity in a motor network

  2022cites this paper
• The Signaling and Pharmacology of the Dopamine D1 Receptor

  2022cites this paper
• Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia

  2022cites this paper
• Striatal ΔFosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats

  2021cites this paper
• Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson’s Disease and L-DOPA-Induced Dyskinesia

  2021cites this paper
• Involvement of Autophagy in Levodopa‐Induced Dyskinesia

  2021cites this paper
• Cerebellar stimulations prevent Levodopa-induced dyskinesia in mice and normalize brain activity

  2021cites this paper
• Levodopa-induced dyskinesias in Parkinson’s disease increase cerebrospinal fluid nitric oxide metabolites’ levels

  2021cites this paper
• Striatal Control of Movement: A Role for New Neuronal (Sub-) Populations?

  2021cites this paper
• The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.

  2021cites this paper
• Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease.

  2021cites this paper
• Fyn Knock-Down Prevents Levodopa-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease

  2021cites this paper
• The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson’s Disease

  2020cites this paper
• Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities

  2020influential citation
• An investigation into the antidyskinetic and reinforcing effects of UWA-101 in Sprague Dawley rats

  2020cites this paper
• Transcriptomic approach predicts a major role for transforming growth factor beta type 1 pathway in L‐Dopa‐induced dyskinesia in parkinsonian rats

  2020cites this paper
• Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia.

  2020cites this paper
• Dopamine D1 receptor signalling in dyskinetic Parkinsonian rats revealed by fiber photometry using FRET-based biosensors

  2020cites this paper
• Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in fisher 344 vs. Lewis hemiparkinsonian rats.

  2020cites this paper
• The Link between Gut Dysbiosis and Neuroinflammation in Parkinsońs Disease.

  2020cites this paper
• Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease.

  2019cites this paper
• Knock-Down of GPR88 in the Dorsal Striatum Alters the Response of Medium Spiny Neurons to the Loss of Dopamine Input and L-3-4-Dyhydroxyphenylalanine

  2019cites this paper
• Classic animal models of Parkinson's disease: a historical perspective.

  2019cites this paper
• Nicotinic acetylcholine receptors in experimental models of Parkinson’s disease and levodopa-induced dyskinesia : focus on α5 subunit-containing receptors

  2019cites this paper
• The Rodent Models of Dyskinesia and Their Behavioral Assessment

  2019influential citation
• Differential Expression of Striatal ΔFosB mRNA and FosB mRNA After Different Levodopa Treatment Regimens in a Rat Model of Parkinson’s Disease

  2019cites this paper
• Chronic administration of the histamine H3 receptor agonist immepip decreases l-Dopa-induced dyskinesias in 6-hydroxydopamine-lesioned rats

  2019cites this paper
• Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD.

  2019cites this paper
• Role of striatal ΔFosB in l-Dopa–induced dyskinesias of parkinsonian nonhuman primates

  2019cites this paper
• Pathophysiological clues to therapeutic applications of glutamate mGlu5 receptor antagonists in levodopa-induced dyskinesia.

  2019cites this paper
• Selective Regulation of 5-HT1B Serotonin Receptor Expression in the Striatum by Dopamine Depletion and Repeated L-DOPA Treatment: Relationship to L-DOPA-Induced Dyskinesias

  2019cites this paper
• Changes in Dendritic Spine Density and Inhibitory Perisomatic Connectivity onto Medium Spiny Neurons in l-Dopa-Induced Dyskinesia

  2019cites this paper
• Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L‐DOPA in a mouse model of Parkinson's disease

  2019cites this paper
• Opioidergic Modulation of Striatal Circuits, Implications in Parkinson's Disease and Levodopa Induced Dyskinesia

  2018cites this paper
• Effects of histone acetyltransferase inhibitors on l-DOPA-induced dyskinesia in a murine model of Parkinson’s disease

  2018cites this paper
• L‐DOPA for Parkinson's disease—a bittersweet pill

  2018cites this paper
• Understanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson’s disease

  2018cites this paper
• Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats

  2018cites this paper
• 5 Imaging Dyskinesias in Parkinson ’ s Disease

  2018cites this paper
• A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia.

  2018cites this paper
• On the neuronal circuitry mediating l-DOPA-induced dyskinesia

  2018cites this paper
• Pre- and postsynaptic dysregulation of dopamine signalling in Parkinson's disease

  2018cites this paper
• A Selective Phosphodiesterase 10A Inhibitor Reduces L‐Dopa‐Induced Dyskinesias in Parkinsonian Monkeys

  2018cites this paper
• Selegiline increases on time without exacerbation of dyskinesia in 6‐hydroxydopamine‐lesioned rats displaying l‐Dopa‐induced wearing‐off and abnormal involuntary movements

  2018cites this paper
• Molecular basis of dopamine replacement therapy and its side effects in Parkinson’s disease

  2018cites this paper
• Impulse control disorders in Parkinson’s disease

  2018cites this paper
• Animal models of l‐dopa‐induced dyskinesia in Parkinson's disease

  2018cites this paper
• Signal transduction in l-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression

  2018cites this paper
• Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias

  2018cites this paper
• Animal models of l-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse

  2018cites this paper
• Chapter 31 - Psychostimulant-Induced Gene Regulation in Striatal Circuits

  2017cites this paper
• Stimulations du cervelet pour le traitement des dyskinésies induites par la lévodopa dans la maladie de Parkinson

  2017cites this paper
• Differences Between Intact and Ovariectomized Hemiparkinsonian Rats in Response to L-DOPA, Melatonin, and L-DOPA/Melatonin Coadministration on Motor Behavior and Cytological Alterations

  2017influential citation
• Dead or alive? The manipulation of neuronal ensembles and pathways by daunorubicin

  2017influential citation
• Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia

  2017cites this paper
• Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms.

  2017cites this paper
• CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors

  2017cites this paper
• Activation of DREAM , a calcium-binding protein , reduces L-DOPA-induced dyskinesias in mice

  2017cites this paper
• Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice

  2017cites this paper
• The Kinase Fyn As a Novel Intermediate in l-DOPA-Induced Dyskinesia in Parkinson’s Disease

  2017cites this paper
• P. (2017). Dead or alive? The manipulation of neuronal ensembles and pathways by daunorubicin. Brain and Neuroscience Advances 1-5.

  2017influential citation
• Phosphodiesterases: CNS Functions and Diseases

  2017cites this paper
• Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.

  2017cites this paper
• Region‐specific bioconversion of dynorphin neuropeptide detected by in situ histochemistry and MALDI imaging mass spectrometry

  2017cites this paper
• Molecular Mechanisms of l-DOPA-Induced Dyskinesia

  2017cites this paper
• Antidyskinetic Effects of MEK Inhibitor Are Associated with Multiple Neurochemical Alterations in the Striatum of Hemiparkinsonian Rats

  2017cites this paper
• Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.

  2016cites this paper
• Signaling mechanisms in L-DOPA-induced dyskinesia

  2016cites this paper
• Striatal NELF-mediated RNA polymerase II stalling controls L-dopa induced dyskinesia.

  2016cites this paper
• l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons.

  2016cites this paper
• Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action.

  2016cites this paper
• Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment

  2016influential citation
• Palmitoyl Serotonin Inhibits L-dopa-induced Abnormal Involuntary Movements in the Mouse Parkinson Model

  2016cites this paper
• Effect of the C-terminal domain of the heavy chain of tetanus toxin on dyskinesia caused by levodopa in 6-hydroxydopamine-lesioned rats.

  2016cites this paper
• Impulse control disorders and dyskinesias in Parkinson’s disease : an update

  2016cites this paper
• Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment

  2016influential citation
• Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment

  2016influential citation
• Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats

  2016cites this paper
• Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.

  2016cites this paper
• Beyond muscles: The untapped potential of creatine.

  2016cites this paper
• Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment

  2016influential citation
• Shp‐2 knockdown prevents l‐dopa‐induced dyskinesia in a rat model of Parkinson's disease

  2016cites this paper
• Quand le cerveau succombe aux addictions: Facteurs de vulnérabilité, implication des circuits cortico-striataux et développement d’une technique de neuromodulation pour favoriser le sevrage

  2016cites this paper
• Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists.

  2016cites this paper
• l‐DOPA‐induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?

  2016cites this paper